{"schema_version":"secwatch.filing_event.v1","accession":"0001388658-22-000149","form_type":"8-K","ticker":"IRTC","cik":"0001388658","company_name":"iRhythm Holdings, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.408202+00:00","generated_at":"2026-06-22T17:41:51.699454+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"iRhythm Q3 revenue $103.9M (+21.6% YoY); cuts FY22 revenue guidance to $407-411M","bullets":["Revenue $103.9M (+21.6% YoY); net loss $21.5M ($0.71/sh) vs $23.7M loss in Q3 2021.","Gross margin 68.3%, up 2.6pp from 65.7% in Q3 2021.","FY22 revenue guidance lowered to $407-411M from prior $415-420M (approx 26-27% YoY growth).","Adjusted EBITDA guidance improved to -$10 to -$12M from prior -$12.5 to -$17.5M; adjusted opex guidance $360-365M.","Registration volumes +22% YoY; highest daily registrations at Sept end; cited softness in returned devices persisting into Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001388658-22-000149","json":"https://secwatch.observer/filing/0001388658-22-000149.json","markdown":"https://secwatch.observer/filing/0001388658-22-000149.md","text":"https://secwatch.observer/filing/0001388658-22-000149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388658/000138865822000149/0001388658-22-000149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388658/000138865822000149/irtc-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T17:41:51.699454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7136e3676dcc315ed4749e11023097eb170c01af","claim":"iRhythm Holdings, Inc. reported the three months ended September 30, 2022 results: revenue $103.9 million, net income Net loss for the third quarter of 2022 was $21.5 million, or a loss of $0.71 per share, EPS $0.71 per share. Guidance lowered.","evidence_excerpt":"that detect, prevent, and predict disease, today reported financial results for the three months ended September 30, 2022. Third Quarter 2022 Financial Results • Revenue of $103.9 million, a 21.6% increase compared to third quarter 2021 • Gross margin of 68.3%, a 2.6 percentage point improvement compared to third quarter 2021 • Cash, cash equivalents and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1388658/000138865822000149/0001388658-22-000149-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$103.9 million"},{"label":"Net income","value":"Net loss for the third quarter of 2022 was $21.5 million, or a loss of $0.71 per share"},{"label":"EPS","value":"$0.71 per share"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}